Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.J Natl Cancer Inst. 2014; 106: dju055
- Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer.N Engl J Med. 2020; 383: 2557-2570
- Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient level meta-analysis of randomised trials.Lancet. 2011; 378: 771-784
- Eighth edition of the AJCC Cancer staging manual: breast cancer.Ann Surg Oncol. 2018; 25: 1783-1785
- Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2019; 30: 1194-1220
- Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update.J Clin Oncol. 2020; 38: 1346-1366
- A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N Engl J Med. 2004; 351: 2817-2826
- Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.J Clin Oncol. 2006; 24: 3726-3734
- Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.N Engl J Med. 2018; 379: 111-121
- Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer.J Clin Oncol. 2021; 39: 557-564
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.N Eng J Med. 2021; 385: 2336-2347
- A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.Cancer. 2022; 128: 2209-2223
- Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.J Natl Cancer Inst. 2006; 98: 1183-1192
- for the MINDACT Investigators. 70-gene signature as an aid to treatment decisions in early-stage breast cancer.N Engl J Med. 2016; 375: 717-729
- Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.Ann Oncol. 2015; 26: 1685-1691
- Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.J Clin Oncol. 2013; 31: 2783-2790
- Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.Lancet Oncol. 2013; 14: 1067-1076
- Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.Ann Oncol. 2019; 30: 1776-1783
- Breast cancer (version 7.2021).https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfDate accessed: August 8, 2022
- Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx.J Clin Oncol. 2019; 37: 1956-1964
- Customising local and systemic therapies for women with early breast cancer: the St Gallen International Consensus Guidelines for treatment of early breast cancer.Ann Oncol. 2021; 32: 1216-1235.021
- Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.J Clin Oncol. 2002; 20: 4141-4149
- Estrogen receptor status by immuno-histochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.J Clin Oncol. 1999; 17: 1474-1481
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.Lancet. 2015; 386: 1341-1352
- Aromatase inhibitors and breast cancer.N Engl J Med. 2003; 348: 2431-2442
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.Lancet Oncol. 2010; 11: 1135-1141
- for the members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial.J Clin Oncol. 2019; 37: 105-114
- Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Ann Oncol. 2011; 22: 2201-2207
- Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial.J Clin Oncol. 2015; 33: 2772-2779
- Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence.J Clin Oncol. 2016; 34: 2452-2459
- Management of aromatase inhibitorinduced musculoskeletal symptoms.JCO Oncol Pract. 2020; 16: 733-739
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.Lancet Oncol. 2011; 12: 1101-1108
- on behalf of the SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2018; 19: 127-138
- 20- Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years.N Engl J Med. 2017; 377: 1836-1846
- Factors predicting late recurrence for estrogen receptor-positive breast cancer.J Natl Cancer Inst. 2013; 105: 1504-1511
- Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO Clinical Practice Guideline focused update.J Clin Oncol. 2019; 37: 423-438
- Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.N Engl J Med. 2021; 385: 395-405
- Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women.Cancer Res. 2019; 79 (Abstract GS3-03)
- Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).J Clin Oncol. 2017; 35: 2647-2655
- behalf of the West German Study Group PlanB Investigators. West German Study PlanB Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer.J Clin Oncol. 2019; 37: 799-808
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.Lancet. 2015; 386: 1353-1361
- Breast cancer.Nat Rev Dis Primers. 2019; 5: 66
- Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.PLoS ONE. 2022; 17 (Available at:): e0264637https://doi.org/10.1371/journal.pone.0264637
- Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.Lancet. 2020; 395: 817-827
- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.Lancet Oncol. 2021; 22: 212-222
- Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).J Clin Oncol. 2022; 40: 282-293
- Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the Penelope-B trial.J Clin Oncol. 2021; 39: 1518-1530
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).J Clin Oncol. 2020; 38: 3987-3998
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.Ann Oncol. 2021; 32: 1571-1581
- FDA Approval Summary: Abemaciclib with endocrine therapy for high-risk early breast cancer.J Clin Oncol. 2022; 40: 1155-1162
- Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer: ASCO optimal adjuvant chemotherapy and targeted therapy guideline rapid recommendation update.J Clin Oncol. 2022; 40: 307-309
- Testing endocrine response for managing primary estrogen receptor-positive breast cancer.J Clin Oncol. 2022; 40: 2520-2523
- Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multi-centre, parallel-group, randomised, phase 3 trial.Lancet Oncol. 2020; 21: 1443-1454
- Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer; results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance.) J Clin Oncol. 2017; 35: 1061-1069
- Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+/HER2- early breast cancer.J Clin Oncol. 2022; 40: 2557-2567
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
